Afyx Therapeutics

Afyx Therapeutics is a biopharmaceutical company focused on innovative approaches to the treatment of mucosal diseases. For this purpose, Afyx Therapeutics has developed the Rivelin® patch, designed to deliver a pharmaceutical drug uni-directional to a mucosal surface – using an occlusive, bio-adhesive and bio-degradable patch, with a long adhesion time and a high flexibility, conforming to the mucosal surface.

Afyx Therapeutics’ lead product candidate incorporates clobetasol proprionate to the Rivelin® patch targeting the currently unmet need of treating Oral Lichen Planus, a chronic condition that affect 1-2% of the population. This product candidate is currently in Phase 1b, with commencement of Phase 2b planned for 4Q 2017

Contact name:

Lars Siim Madsen


Lergravsvej 57, 2. tv., 2300 Copenhagen S, Denmark



Number of employees:


If you cannot find what you are looking for or if you have feedback to our website, please do not hesitate to contact or +45 7172 1114

Copyright 2017 DANISH BIO – DANSK BIOTEK. All rights reserved.